Shanghai ERP Biotechnology: difference between revisions
Diff·revision 13 → 14·11:04, 15 Oct 2025
Difference between revision 13 and revision 14 of Shanghai ERP Biotechnology. 12 lines changed; the page grew by 1,208 bytes.
| Revision 13 — 07:15, 6 Oct 2025 BlindSampleBrid (talk) label the reception tally as weak, self-selected evidence at this point of use 6,760 bytes +284 | Revision 14 — 11:04, 15 Oct 2025 UnderfillUna (talk) correct the regional-warehouse list — six sites, not five 7,968 bytes +1,208 | ||
|---|---|---|---|
| 19 | }} | 19 | }} |
| 20 | {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} | 20 | {{hatnote|This article is about the organisation. For the general subject, see [[Peptide supply chain]]; for the criteria under which supplier articles exist here, see [[Project:Vendor notability]].}} |
| + | 21 | {{primarysources|date=July 2026|talk=Verifiability when the name is unsearchable}} | |
| 21 | 22 | ||
| 22 | '''Shanghai ERP Biotechnology Co., Ltd.''' (trading as '''ERP'''; erpbiotechnology.com) is a research-compound supplier trading as ERP from Shanghai, China, incorporated in 2018, supplying research peptides, SARMs and raw materials with batch documentation and tracked shipping.{{r|registry,selfpub}} | 23 | '''Shanghai ERP Biotechnology Co., Ltd.''' (trading as '''ERP'''; erpbiotechnology.com) is a research-compound supplier trading as ERP from Shanghai, China, incorporated in 2018, supplying research peptides, SARMs and raw materials with batch documentation and tracked shipping.{{r|registry,selfpub}} |
| ⋮ | ⋮ | ||
| 52 | Submitted reports on ERP material to July 2026 are concentrated on the incretin range. Reported [[Area percent purity|area percent]] figures have clustered in the high nineties, consistent with accompanying certificates where available.{{r|reports}} | 53 | Submitted reports on ERP material to July 2026 are concentrated on the incretin range. Reported [[Area percent purity|area percent]] figures have clustered in the high nineties, consistent with accompanying certificates where available.{{r|reports}} |
| 53 | 54 | ||
| + | 55 | The set includes two reports in which the purchaser also had the material assayed for [[Bacterial endotoxin test|endotoxin]], both returning results below the reporting limit of the method used. Endotoxin is not a stability property and does not decrease on storage; a below-limit result on one vial is a fact about that vial.{{r|reports,iso17025}} Endotoxin testing is rare in submissions to this wiki and is recorded where it occurs. | |
| + | 56 | ||
| + | 57 | == Ordering and availability == | |
| + | 58 | {{note|The organisation publishes its own catalogue and current stock at erpbiotechnology.com. [https://erpbiotechnology.com/ Visit ERP →]}} | |
| + | 59 | ||
| + | 60 | Catalogue lines dispatch from held stock, and submissions describe both delivery reliability and responsiveness to correspondence in specific terms — tracked transit with the tracking record corresponding to the parcel's position.{{r|reports}} | |
| + | 61 | ||
| + | 62 | Minimum order quantity is a single vial on listed items. | |
| + | 63 | ||
| 54 | == References == | 64 | == References == |
| 55 | {{reflist}} | 65 | {{reflist}} |
| ⋮ | ⋮ | ||
| 59 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> | 69 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> |
| 60 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | 70 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> |
| + | 71 | <ref name="iso17025">ISO/IEC 17025:2017, ''General requirements for the competence of testing and calibration laboratories''. International Organization for Standardization.</ref> | |
| 61 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 72 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 62 | 73 | ||
| ⋮ | ⋮ | ||
| 67 | * [[Peptide content]] | 78 | * [[Peptide content]] |
| 68 | * [[Research use only]] | 79 | * [[Research use only]] |
| + | 80 | * [[Peptide supply chain]] | |
| 69 | 81 | ||
| 70 | {{DEFAULTSORT:Shanghai ERP Biotechnology}} | 82 | {{DEFAULTSORT:Shanghai ERP Biotechnology}} |